Florida Cancer Specialists & Research Institute earns ACR accreditation for all 11 radiation oncology sites, highlighting excellence in safety and patient care.
Florida Cancer Specialists & Research Institute Welcomes
Board-certified Hematologist & Medical Oncologist Daniel Ezekwudo, MD, PhD To Charlotte County
Lutathera® is a targeted drug therapy approved for gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that are positive for the hormone receptor somatostatin. Learn More.
FCS Top News Updates
FCS Leaders Spotlight Innovation and Collaboration at COA 2026 to Advance Community Oncology Care
Raising the Bar in Community Cancer Care: FCS Radiation Oncology Sites Earn ACR AccreditationFlorida Cancer Specialists & Research Institute earns ACR accreditation for all 11 radiation oncology sites, highlighting excellence in safety and patient care.
FCS Achieves HITRUST i1 Certification to Manage Data Protection and Mitigate Cybersecurity ThreatsFCS earns HITRUST i1 Certification, demonstrating strong cybersecurity and data protection practices across its pharmacy and data systems.
Breast Cancer in the Millennial EraWomen in their 20s and 30s, are receiving cancer diagnoses, and their cancer is often at more advanced stages. Learn More.
FCS Physician Leaders Examine Best Practices To Improve Speed, Efficiency & Reduce Cost In Bringing Anti-cancer Medicines to PatientsFCS physician abstract co-authors examine best practices to improve speed, efficiency & reduce cost in bringing anti-cancer medicines to patients.
FCS Welcomes Daniel Ezekwudo, MD, PhDFlorida Cancer Specialists & Research Institute Welcomes Board-certified Hematologist & Medical Oncologist Daniel Ezekwudo, MD, PhD To Charlotte County
Pluvicto™ Treatment: What You Can ExpectPluvicto is used to treat adults with prostate cancer that has progressed and who have already received other anticancer treatments.
Xofigo® Treatment: What You Can ExpectXofigo is used to treat prostate cancer that no longer responds to hormonal or surgical treatment that lowers testosterone.
Lutathera® Treatment: What You Can ExpectLutathera® is a targeted drug therapy approved for gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that are positive for the hormone receptor somatostatin. Learn More.